Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation
出版年份 2018 全文链接
标题
Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation
作者
关键词
Adverse events, Neutrophils, Adverse reactions, Nontuberculous mycobacteria, White blood cells, Blood, Cystic fibrosis, Inflammation
出版物
PLoS One
Volume 13, Issue 12, Pages e0209026
出版商
Public Library of Science (PLoS)
发表日期
2018-12-13
DOI
10.1371/journal.pone.0209026
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor
- (2016) Preston E. Bratcher et al. Journal of Cystic Fibrosis
- Low expression of CXCR1/2 on neutrophils predicts poor survival in patients with hepatitis B virus-related acute-on-chronic liver failure
- (2016) Ruonan Xu et al. Scientific Reports
- Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation
- (2014) Kris De Boeck et al. Journal of Cystic Fibrosis
- Cystic Fibrosis Pulmonary Guidelines
- (2013) Peter J. Mogayzel et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Cystic Fibrosis Chronic Rhinosinusitis: A Comprehensive Review
- (2013) Mohamad R. Chaaban et al. American Journal of Rhinology & Allergy
- Systematic Review of Blood Biomarkers in Cystic Fibrosis Pulmonary Exacerbations
- (2013) Alborz Hakimi Shoki et al. CHEST
- Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function
- (2013) Fredrick Van Goor et al. Journal of Cystic Fibrosis
- Extensive Surgical and Comprehensive Postoperative Medical Management for Cystic Fibrosis Chronic Rhinosinusitis
- (2012) Frank W. Virgin et al. American Journal of Rhinology & Allergy
- Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis
- (2012) Richard B. Moss et al. Journal of Cystic Fibrosis
- Milk Fat Globule-Epidermal Growth Factor-Factor 8 Attenuates Neutrophil Infiltration in Acute Lung Injury via Modulation of CXCR2
- (2012) M. Aziz et al. JOURNAL OF IMMUNOLOGY
- CXCR1andCXCR2haplotypes synergistically modulate cystic fibrosis lung disease
- (2011) Michael S.D. Kormann et al. EUROPEAN RESPIRATORY JOURNAL
- Translocated LPS Might Cause Endotoxin Tolerance in Circulating Monocytes of Cystic Fibrosis Patients
- (2011) Rosa del Campo et al. PLoS One
- Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
- (2011) F. Van Goor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Decreased CXCR1 and CXCR2 expression on neutrophils in anti-neutrophil cytoplasmic autoantibody-associated vasculitides potentially increases neutrophil adhesion and impairs migration
- (2011) Nan Hu et al. ARTHRITIS RESEARCH & THERAPY
- Molecular Pathways of Spontaneous and TNF-α–Mediated Neutrophil Apoptosis under Intermittent Hypoxia
- (2010) Larissa Dyugovskaya et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- Comparing two small samples with an unstable, treatment-independent baseline
- (2009) Skirmantas Janušonis JOURNAL OF NEUROSCIENCE METHODS
- Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
- (2009) F. Van Goor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CXCR2 antagonists for the treatment of pulmonary disease
- (2008) R.W. Chapman et al. PHARMACOLOGY & THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More